NASDAQ:UTHR - United Therapeutics Stock Price, Price Target & More

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics declared that its Board of Directors has approved a stock buyback program on Sunday, June 4th 2017, which allows the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 4.6% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to the consensus estimate of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.61 earnings per share. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for United Therapeutics.

8 brokers have issued 12 month price objectives for United Therapeutics' stock. Their forecasts range from $95.00 to $232.00. On average, they expect United Therapeutics' stock price to reach $130.75 in the next year. View Analyst Ratings for United Therapeutics.

Some companies that are related to United Therapeutics include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Nektar Therapeutics (NKTR), Ono Pharmaceutical (OPHLF), Genmab (GNMSF), Merck Group (MKGAF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).

Media headlines about UTHR stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

United Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.28%), Palo Alto Investors LP (3.73%), Old Mutual Global Investors UK Ltd. (2.21%), Dimensional Fund Advisors LP (2.20%), FIL Ltd (1.48%) and Thompson Siegel & Walmsley LLC (1.25%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Wells Fargo & Company MN, Royal Bank of Canada, Millennium Management LLC, BNP Paribas Arbitrage SA, Thompson Siegel & Walmsley LLC, Swiss National Bank and State of Tennessee Treasury Department. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.

UTHR stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, BlackRock Inc., Mackay Shields LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., UBS Group AG, Senzar Asset Management LLC and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $103.60.

United Therapeutics has a market capitalization of $4.60 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]